De Vries T J, Shaham Y, Homberg J R, Crombag H, Schuurman K, Dieben J, Vanderschuren L J, Schoffelmeer A N
Research Institute Neurosciences Vrije Universiteit, Department of Medical Pharmacology, VU Medical Center, Amsterdam, The Netherlands.
Nat Med. 2001 Oct;7(10):1151-4. doi: 10.1038/nm1001-1151.
Treatment of cocaine addiction is hampered by high rates of relapse even after prolonged drug abstinence. This relapse to compulsive cocaine use can be triggered by re-exposure to cocaine, by re-exposure to stimuli previously associated with cocaine or by exposure to stress. In laboratory rats, similar events reinstate cocaine seeking after prolonged withdrawal periods, thus providing a model to study neuronal mechanisms underlying the relapse to cocaine. The endocannabinoid system has been implicated in a number of neuropsychiatric conditions, including drug addiction. The active ingredient of marijuana, Delta9-tetrahydrocannabinol, activates the mesolimbic dopamine (DA) reward system and has rewarding effects in preclinical models of drug abuse. We report here that the synthetic cannabinoid agonist, HU210 (ref. 13), provokes relapse to cocaine seeking after prolonged withdrawal periods. Furthermore, the selective CB1 receptor antagonist, SR141716A (ref. 14), attenuates relapse induced by re-exposure to cocaine-associated cues or cocaine itself, but not relapse induced by exposure to stress. These data reveal an important role of the cannabinoid system in the neuronal processes underlying relapse to cocaine seeking, and provide a rationale for the use of cannabinoid receptor antagonists for the prevention of relapse to cocaine use.
即使经过长时间的药物戒断,可卡因成瘾的治疗仍因高复发率而受阻。重新接触可卡因、重新接触先前与可卡因相关的刺激因素或接触压力,都可能引发这种复吸至强迫性使用可卡因的情况。在实验大鼠中,类似事件会在长时间戒断后恢复可卡因觅求行为,从而提供了一个研究可卡因复吸背后神经元机制的模型。内源性大麻素系统与包括药物成瘾在内的多种神经精神疾病有关。大麻的活性成分Δ9-四氢大麻酚会激活中脑边缘多巴胺(DA)奖赏系统,并在药物滥用的临床前模型中产生奖赏效应。我们在此报告,合成大麻素激动剂HU210(参考文献13)会在长时间戒断后引发可卡因觅求行为的复发。此外,选择性CB1受体拮抗剂SR141716A(参考文献14)可减弱因重新接触与可卡因相关的线索或可卡因本身所诱导的复发,但不能减弱因接触压力所诱导的复发。这些数据揭示了大麻素系统在可卡因觅求行为复发背后的神经元过程中的重要作用,并为使用大麻素受体拮抗剂预防可卡因使用复发提供了理论依据。